1. Home
  2. ALT vs PRTA Comparison

ALT vs PRTA Comparison

Compare ALT & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • PRTA
  • Stock Information
  • Founded
  • ALT 1997
  • PRTA 2012
  • Country
  • ALT United States
  • PRTA Ireland
  • Employees
  • ALT N/A
  • PRTA N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • PRTA Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALT Health Care
  • PRTA Health Care
  • Exchange
  • ALT Nasdaq
  • PRTA Nasdaq
  • Market Cap
  • ALT 292.0M
  • PRTA 472.1M
  • IPO Year
  • ALT N/A
  • PRTA N/A
  • Fundamental
  • Price
  • ALT $3.83
  • PRTA $8.20
  • Analyst Decision
  • ALT Strong Buy
  • PRTA Buy
  • Analyst Count
  • ALT 6
  • PRTA 10
  • Target Price
  • ALT $17.40
  • PRTA $14.86
  • AVG Volume (30 Days)
  • ALT 3.0M
  • PRTA 1.2M
  • Earning Date
  • ALT 08-12-2025
  • PRTA 08-04-2025
  • Dividend Yield
  • ALT N/A
  • PRTA N/A
  • EPS Growth
  • ALT N/A
  • PRTA N/A
  • EPS
  • ALT N/A
  • PRTA N/A
  • Revenue
  • ALT $20,000.00
  • PRTA $10,341,000.00
  • Revenue This Year
  • ALT N/A
  • PRTA N/A
  • Revenue Next Year
  • ALT $761,880.20
  • PRTA $389.77
  • P/E Ratio
  • ALT N/A
  • PRTA N/A
  • Revenue Growth
  • ALT N/A
  • PRTA N/A
  • 52 Week Low
  • ALT $2.90
  • PRTA $4.32
  • 52 Week High
  • ALT $11.16
  • PRTA $22.83
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • PRTA 58.73
  • Support Level
  • ALT $3.35
  • PRTA $8.05
  • Resistance Level
  • ALT $3.66
  • PRTA $8.73
  • Average True Range (ATR)
  • ALT 0.19
  • PRTA 0.38
  • MACD
  • ALT 0.07
  • PRTA -0.05
  • Stochastic Oscillator
  • ALT 86.18
  • PRTA 47.62

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Share on Social Networks: